J P O'Neill1, D Power, C Condron, D Bouchier-Hayes, M Walsh. 1. The Department of Otolaryngology, The Royal College of Surgeons in Ireland, Beaumont Hospital, The Education and Research Building, Beaumont, Dublin 9, Ireland. joneill@rcsi.ie
Abstract
BACKGROUND: Anaplastic thyroid cancer (ATC) is a fatal endocrine malignancy. Current therapy fails to significantly improve survival. Recent insights into thyroid tumorigenesis, post-malignant dedifferentiation and mode of metastatic activity offer new therapeutic strategies. METHODS: An extensive literature search of Medline and Pubmed was conducted to include all published reports on ATC. Secondary articles were identified from key paper reference listings. CONCLUSIONS: Significant progress, in the last 5 years, has been made outlining thyroid tumorigenesis and the progression to anaplasia. Continued identification and development of drug therapies is required to counter specific molecular targets responsible for the post-malignant dedifferentiation process and ultimately the fatal neoplastic phenotype.
BACKGROUND:Anaplastic thyroid cancer (ATC) is a fatal endocrine malignancy. Current therapy fails to significantly improve survival. Recent insights into thyroid tumorigenesis, post-malignant dedifferentiation and mode of metastatic activity offer new therapeutic strategies. METHODS: An extensive literature search of Medline and Pubmed was conducted to include all published reports on ATC. Secondary articles were identified from key paper reference listings. CONCLUSIONS: Significant progress, in the last 5 years, has been made outlining thyroid tumorigenesis and the progression to anaplasia. Continued identification and development of drug therapies is required to counter specific molecular targets responsible for the post-malignant dedifferentiation process and ultimately the fatal neoplastic phenotype.
Authors: Tae Yong Kim; Kyung Won Kim; Tae Sik Jung; Jung Min Kim; Sun Wook Kim; Ki-Wook Chung; Eun Young Kim; Gyungyub Gong; Young Lyun Oh; Soo Youn Cho; Ka Hee Yi; Won Bae Kim; Do Joon Park; Jae Hoon Chung; Bo Youn Cho; Young Kee Shong Journal: Head Neck Date: 2007-08 Impact factor: 3.147
Authors: Sam M Wiseman; Hamid Masoudi; Paddy Niblock; Dmitry Turbin; Ashish Rajput; John Hay; Douglas Filipenko; David Huntsman; Blake Gilks Journal: Am J Surg Date: 2006-05 Impact factor: 2.565
Authors: Seungwon Kim; Christopher N Prichard; Maher N Younes; Yasemin D Yazici; Samar A Jasser; B Nebiyou Bekele; Jeffrey N Myers Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: Sam M Wiseman; Thom R Loree; Nestor R Rigual; Wesley L Hicks; Wade G Douglas; Garth R Anderson; Daniel L Stoler Journal: Head Neck Date: 2003-08 Impact factor: 3.147
Authors: A S Rocha; P Soares; E Fonseca; J Cameselle-Teijeiro; M C Oliveira; M Sobrinho-Simões Journal: Histopathology Date: 2003-06 Impact factor: 5.087
Authors: Salvatore Ulisse; Jean-Guy Delcros; Enke Baldini; Matteo Toller; Francesco Curcio; Laura Giacomelli; Claude Prigent; Francesco S Ambesi-Impiombato; Massimino D'Armiento; Yannick Arlot-Bonnemains Journal: Int J Cancer Date: 2006-07-15 Impact factor: 7.396
Authors: Subrata Chowdhury; Joe Veyhl; Fatima Jessa; Olena Polyakova; Ahmed Alenzi; Christina MacMillan; Ranju Ralhan; Paul G Walfish Journal: Oncotarget Date: 2016-05-31